1 / 11

Advanced NSCLC

Advanced NSCLC. Objective response rate Well defined & widely accepted Does not correlate well with OS May be more useful if SD included Higher RR correlates with sx benefit. Advanced NSCLC. Time to tumor progression Poorly defined, not standardized

barb
Download Presentation

Advanced NSCLC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advanced NSCLC • Objective response rate • Well defined & widely accepted • Does not correlate well with OS • May be more useful if SD included • Higher RR correlates with sx benefit

  2. Advanced NSCLC • Time to tumor progression • Poorly defined, not standardized • Relationship to patient benefit is unknown • Rough correlation with OS (MST ≈ TTPx2

  3. Advanced NSCLC • Overall survival • Definitive endpoint • Most commonly used endpoint • Easily determined; hard to “fudge” • Survival benefit attributable to therapy in well designed phase III trial

  4. Advanced NSCLC • Percent progression at defined time • Not a traditional endpoint • Association with pt benefit is unknown • Use of this endpoint implies that SD pts have a survival outcome similar to those with rumor regression • Retrospective data suggest NON-PD at a predetermined point correlates with OS

  5. Phase II Trial DesignNew Paradigms for Novel Agents • Set maximum PD rate above which agent will be rejected. • PD rate of interest will vary according to tumor type.

  6. NCIC NSCLC TrialSurvival of Stable & PR vs PD

  7. Survival Significance of SD: Landmark Analysis of E5592 & E1594:

  8. Phase II Trial DesignNew Paradigms for Novel Agents • Goal of phase II trial is to screen agent for efficacy. • Traditionally, this is measured by objective response rate using standard criteria. • ORR correlates with ‘efficacy’ (i.e. survival).

  9. Phase II Trial DesignNew Paradigms for Novel Agents • More common scenario is growth delay not tumor regression. • Candidate endpoints: changes in tumor markers, target inhibition measures; PET scanning; TTP; percent early PD. • None yet validated

More Related